The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Cardiovasc. Med.
Sec. Cardiovascular Imaging
Volume 11 - 2024 |
doi: 10.3389/fcvm.2024.1406470
First-in-human cases and preclinical experience of a novel ICE catheter
Provisionally accepted- 1 Suzhou Kowloon Hospital, Suzhou, Jiangsu Province, China
- 2 Suzhou Kowloon Hospital, Suzhou, Liaoning Province, China
- 3 Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing Municipality, China
- 4 Zhongshan Hospital, Fudan University, Shanghai, Shanghai Municipality, China
- 5 ICE Intelligent Healthcare Co.,Ltd, Suzhou, China
To verify the safety and effectiveness of the novel intracardiac echocardiography (ICE) catheter, we conducted a First-in-Human study and preclinical in vitro tests, comparing it with established commercial ICE catheters. This report describes the utilization of the new ICE catheter in aiding arrhythmias electrophysiology ablation, with a comparative analysis of its performance against existing competitors in porcine models. Background Since the 1960s, the use of intracardiac echocardiography (ICE) catheters has been showcased globally. Notably, in 1981, Glassman and Kronzon made a significant contribution by embedding a 7.5MHz ultrasonic into a flexible coaxial cable, which was then utilized in 20 patients 1 . Although the prototype emerged early, technological advances in ICE have not kept pace with those of its peers. Furthermore, it's noteworthy that ultrasound imaging is the only major medical imaging modality for which no one has been awarded a Nobel Prize, since the development depending on many prior insights from physics 2 . In 2000, the first phased-array AcuNAV 10 French (10F) catheter (Johnson and Johnson MedTech) was introduced to global market, and since then, it has maintained a dominant position for more than 20 years. With the onset of the new century, rapid developments in fields such as structural heart and electrophysiology diseases have propelled ICE into new applications 3,4,5,6 . The demand of visualizing small cardiac structures, including valves, left atrial appendage and left atrial wall, has driven the adoption of 3D and 4D ICE 6,7,8,9 . In comparison to the well-stablished transesophageal echocardiography (TEE), ICE presents unique advantages, offering high spatial resolution for imaging at short distances and eliminating the need for general anesthesia 8,10,11 . Despite its cost disadvantage, ICE has demonstrated its value in various intervention procedures. Meanwhile, besides the AcuNAV and ViewFlex ICE (Abbott Laboratories) catheters,
Keywords: Intracardiac echocardiography (Ice), Paroxysmal supraventricular tachycardia (PSVT), atrial fibrillation (AF), image quality, Endocardial damage
Received: 25 Mar 2024; Accepted: 26 Aug 2024.
Copyright: © 2024 Liu, Wu, Fang, Zhao, Sun, Zhang, Liu, Wang and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Feng Liu, Suzhou Kowloon Hospital, Suzhou, Jiangsu Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.